SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Regorafenib is a treatment option for refractory metastatic colorectal cancer (mCRC) patients. The identification of markers to predict or monitor the efficacy of regorafenib represents a key issue in this palliative setting. In a previous exploratory study, the early increase of Ang-2 plasma levels during treatment with regorafenib seemed to predict benefit from this agent and low baseline Ang-2 and Tie-2 plasma levels were associated with good...